Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment387% Female56%% WhiteN/A
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-INT-2Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)75
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0840 : Gender differences in the efficacy of anti-dementia medication in Alzheimer’s disease: a systematic review
- 2023-5295 : Individual-level and study-level predictors of neuropsychiatric symptom placebo response in Alzheimer?s Disease clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2020-4324 : Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in AD, PD and DLB
- 2017-1671 : Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and IPD NMA
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The ?Optimising the Analysis of Cognition? Collaboration
- 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques